Carboplatin and paclitaxel induction chemotherapy for patients with oropharynx carcinoma;Neoadjuvante chemotherapie von oropharynxkarzinomen mit carboplatin und paclitaxel

Laryngo- Rhino- Otologie

Volumn 87, Issue 10, 2008, Pages 719-722

  Schneider, Ihne ^a   Holzgraefe, M ^b   Schroder M ^c  

^a ASKLEPIOS KLINIK ALTONA   (Germany)

^b HNO Klinik Wolfsburg

^c HNO Klinik des Klinikums Kassel   (Germany)

Author keywords

Induction chemotherapy; Oropharynx cacinoma; Paclitaxel carboplatin

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 54549088870     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1077307     Document Type: Article

References (17)

1. Airoldi M, Cattel L, Marchionatti S, Recalenda V, Pedani F, Tagini V, Bumma C, Beatrice F, Succo G, Maria GA. Docetaxel and vinorelbine in recurrent head and neck cancer; pharmacokinetic and clinical results. Am J Clin Oncol 2003; 26: 378-381
2. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR. Docetaxel: an active Drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14 (5): 1672-1678
3. Forastiere AA. Fourth research workshop in the biology, prevention and treatment of head and neck cancer: Eastern Cooperative Oncolgy Group (EOCG) paclitaxel studies in advanced head and neck cancer. Arlington Press, 1994
4. Fountzilas G, Athanassiades A, Kalogera-Fountzila A, Samantas E, Bacoyiannis C, Briassoulis E, Pavlidis N, Kosmidis P, Skarlos D. Paclitaxel in combination with Carboplatin or gemcitabine for the treatment of advanced head and neck cancer. Semin Oncol 1997; 24: S19
5. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of doxetaxel and cisplatin combination Therapybin patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20: 1539-1599
6. Mossmann P, Egli F, Stahel RA, Jost L. Weekly Paclitaxel and Carboplatin combination therapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie 2003; 26: 568-572
7. Schoffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Studies Group. Ann Oncol 1999; 10 (1): 119-122
8. Schrijvers D, Van Herpen C et al. Docetaxel, cisplatin an 5-flourouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 2004; 15 (4): 638-645
9. Stathopulos GP, Rigatos S, Papakostas P, Fountzilas G. Effectivness of paclitaxel and carboplatin combination in heavily pretreatet patients with head and neck cancers. Eur J Cancer 1997; 33 (11): 1780-1783
10. Verweij J. Docetaxel: an interesting new drug for the tratment of head and neck cancer and soft tissue sarcomas. Anticancer Drugs 1995; 6 suppl 4: 19-24
11. Volling P, Schroeder M, Eckel H, Ebeling O, Stennert E. Results of a prospective randomized trial with induction chemotherapy for cancer of the oral cavity and tonsils. HNO 1999; 47: 899-906
12. Posner MR. Paradigm shift in the tratment of head and neck cancer: the role of neoadjuvant Chemotherapy. Oncologist 2005; 10 Suppl 3: 11-19
13. Colevas AD, Busse PM et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998; 16 (4): 1331-1339
14. Zhen W, Karnell LH, Hoffman HT, Funk GF, Buatti JM, Menck HR. The National Cancer Data Base report on squamous cell carcinoma of the base of tongue. Head Neck 2004 Aug; 26 (8): 660-674
15. Layland MK, Sessions DG, Lenox J. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: NO versus N+. Laryngoscope 2005 Apr; 115 (4): 629-639
16. Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, Maraudas P, Coche-Dequeant B, Stromboni-Luboinski M, Sancho-Garnier H, Luboinski B. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000 Dec; 83 (12): 1594-1598
17. Eckardt A, Rades D, Rudat V, Hofele C, Dammer R, Dietl B, Wildfang I, Karstens JH. Prospective phase II study of neoadjuvant radiochemotherapy in advanced operable carcinoma of the mouth cavity. 3-year outcome. Mund Kiefer Gesichtschir 2002 Mar; 6 (2): 117-121